Cargando…
Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
OBJECTIVE: Dihydropyrimidine dehydrogenase (DPYD) genotype is closely associated with fluoropyrimidine (FP)‐induced toxicities in Caucasian population and European Medicines Agency now recommends DPYD genotype‐based FP dosing strategy. PATIENTS AND METHODS: The current study aimed to investigate the...
Autores principales: | Kanai, Masashi, Kawaguchi, Takahisa, Kotaka, Masahito, Manaka, Dai, Hasegawa, Junichi, Takagane, Akinori, Munemoto, Yoshinori, Kato, Takeshi, Eto, Tetsuya, Touyama, Tetsuo, Matsui, Takanori, Shinozaki, Katsunori, Matsumoto, Shigemi, Mizushima, Tsunekazu, Mori, Masaki, Sakamoto, Junichi, Ohtsu, Atsushi, Yoshino, Takayuki, Saji, Shigetoyo, Matsuda, Fumihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134304/ https://www.ncbi.nlm.nih.gov/pubmed/36524458 http://dx.doi.org/10.1002/cam4.5541 |
Ejemplares similares
-
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
por: Kotaka, Masahito, et al.
Publicado: (2018) -
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial
por: Yoshino, Takayuki, et al.
Publicado: (2019) -
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015) -
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer
por: Yoshino, Takayuki, et al.
Publicado: (2019) -
Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)